Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
LetterLetters to the Editor

ABCG2- and ABCB1 Inhibition Using Supratherapeutic Doses of Erlotinib: Clinical Implications in the Treatment of Central Nervous System Metastases

Eveline A. van de Stadt, Maqsood Yaqub, Idris Bahce and N.H. Hendrikse
Journal of Nuclear Medicine February 2020, 61 (2) 305; DOI: https://doi.org/10.2967/jnumed.119.235705
Eveline A. van de Stadt
*Amsterdam UMC, VUmc De Boelelaan 1117 Amsterdam, Netherlands 1081HV E-mail:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: e.vandestadt@amsterdamumc.nl
Maqsood Yaqub
*Amsterdam UMC, VUmc De Boelelaan 1117 Amsterdam, Netherlands 1081HV E-mail:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: e.vandestadt@amsterdamumc.nl
Idris Bahce
*Amsterdam UMC, VUmc De Boelelaan 1117 Amsterdam, Netherlands 1081HV E-mail:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: e.vandestadt@amsterdamumc.nl
N.H. Hendrikse
*Amsterdam UMC, VUmc De Boelelaan 1117 Amsterdam, Netherlands 1081HV E-mail:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: e.vandestadt@amsterdamumc.nl
  • Article
  • Info & Metrics
  • PDF
Loading

TO THE EDITOR: We read with great interest the article by Bauer et al. titled “A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood–Brain Barrier.” They concluded that ABCB1 inhibition by tariquidar (an ABCB1 inhibitor) was not able to enhance 11C-erlotinib brain uptake, but supratherapeutic doses of erlotinib (a dual ABCB1/ABCG2 substrate) before PET scanning could increase 11C-erlotinib brain uptake significantly, when 650 mg or more of erlotinib were administered (1). Previous research from our group using elacridar (also an ABCB1 inhibitor) and 11C-erlotinib PET showed that elacridar was ineffective in blocking ABCG2 (2). The present study underlines the major barrier role of ABCG2, as it showed that ABCG2 was also insufficiently targeted by tariquidar to achieve significant inhibition of this efflux pump.

Tyrosine kinase inhibitors (TKIs) directed against epidermal growth factor receptor (EGFR), including erlotinib and osimertinib, are all substrates for ABCB1 and ABCG2 transporters. For erlotinib, we showed that 11C-erlotinib uptake decreased on treatment with erlotinib (150 mg daily) in tumors, but also in liver tissue, due to EGFR saturation and lowering of the specific binding of 11C-erlotinib to the EGFR target (3,4). However, Bauer et al. showed that supratherapeutic doses of erlotinib led to an increase in the brain uptake, probably through saturation of the ABCB1/ABCG2 efflux pumps leading to elevated nonspecific uptake of 11C-erlotinib in the brain as no relevant target EGFR expression is expected in brain tissue.

There is a therapeutic interest in understanding how these efflux pumps can be influenced. Inhibiting erlotinib efflux could benefit EGFR mutation–positive non–small cell lung cancer (NSCLC) patients with metastases of the central nervous system, which are among the most difficult to treat. Especially, leptomeningeal metastases are often refractory to standard dose therapy as a result of lowered anticancer drug concentration in the cerebrospinal fluid. One strategy to achieve control is to use supratherapeutic doses of erlotinib, where doses of 1,500 mg (10 times the standard daily dose of 150 mg/d) once per week were shown to be effective (5). Although this regimen is successful in certain cases, it is restricted by higher toxicity. The Bauer et al. study showed a 27% increase of VT (volume of distribution) and a 94% increase of AUC (area under the curve) at 1,000 mg, implying a significant clinical benefit. However, they also encountered an increase of adverse events in this group up to the point where inclusion was discontinued. Results using a lower dose, that is, 650 mg, showed a similar increase in VT (23%) and still a significant increase in AUC (78%). This implies that this dose could be sufficient to overcome active efflux of erlotinib with less toxicity. This insight could open the door to different scheduling and dosing regimens.

The treatment landscape for EGFR mutation–positive NSCLC is also evolving. The FLAURA trial showed that osimertinib, a third-generation EGFR-TKI, was more effective than first-generation EGFR-TKIs such as erlotinib for both progression free-survival and overall survival, was better tolerable, and achieved excellent control of brain metastases (6). However, despite good brain penetration, leptomeningeal metastatic disease is still a challenge to osimertinib. Here, the present trial design could serve as an example to study the cerebral pharmacokinetics of next-generation EGFR-TKIs such as osimertinib.

Overall, the results of this well-designed and well-conducted study will help to optimize the treatment regimens in EGFR mutation–positive NSCLC patients with central nervous system metastases.

Footnotes

  • Published online Oct. 4, 2019.

  • © 2020 by the Society of Nuclear Medicine and Molecular Imaging.

REFERENCES

  1. 1.↵
    1. Bauer M,
    2. Karch R,
    3. Wulkersdorfer B,
    4. et al
    . A proof-of-concept study to inhibit ABCG2- and ABCB1-mediated efflux transport at the human blood–brain barrier. J Nucl Med. 2019;60:486–491.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Verheijen RB,
    2. Yaqub M,
    3. Sawicki E,
    4. et al
    . Molecular imaging of ABCB1 and ABCG2 inhibition at the human blood-brain barrier using elacridar and 11C-erlotinib PET. J Nucl Med. 2018;59:973–979.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Bahce I,
    2. Yaqub MM,
    3. Errami H,
    4. et al
    . Effects of erlotinib therapy on [11C]erlotinib uptake in EGFR mutated, advanced NSCLC. EJNMMI Res. 2016;6:10.
    OpenUrl
  4. 4.↵
    1. Yaqub M,
    2. Bahce I,
    3. Voorhoeve C,
    4. et al
    . Quantitative and simplified analysis of 11C-erlotinib studies. J Nucl Med. 2016;57:861–866.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Kuiper JL,
    2. Hendriks L,
    3. van der Wekken A,
    4. et al
    . Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis. Lung Cancer. 2015;89:255–261.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Soria JC,
    2. Ohe Y,
    3. Vansteenkiste J,
    4. et al
    . Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113–125.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 61 (2)
Journal of Nuclear Medicine
Vol. 61, Issue 2
February 1, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
ABCG2- and ABCB1 Inhibition Using Supratherapeutic Doses of Erlotinib: Clinical Implications in the Treatment of Central Nervous System Metastases
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
ABCG2- and ABCB1 Inhibition Using Supratherapeutic Doses of Erlotinib: Clinical Implications in the Treatment of Central Nervous System Metastases
Eveline A. van de Stadt, Maqsood Yaqub, Idris Bahce, N.H. Hendrikse
Journal of Nuclear Medicine Feb 2020, 61 (2) 305; DOI: 10.2967/jnumed.119.235705

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
ABCG2- and ABCB1 Inhibition Using Supratherapeutic Doses of Erlotinib: Clinical Implications in the Treatment of Central Nervous System Metastases
Eveline A. van de Stadt, Maqsood Yaqub, Idris Bahce, N.H. Hendrikse
Journal of Nuclear Medicine Feb 2020, 61 (2) 305; DOI: 10.2967/jnumed.119.235705
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Thoughts on “Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality?”
  • Tumor Sink Effect: Myth or Reality?
  • Reply: Posterior Cingulate Involvement Does Not Argue against LATE -- and Who Said It Does?
Show more Letters to the Editor

Similar Articles

SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire